CSF1R and atherosclerosis: During atherosclerosis development, the expression of M-CSFR in infiltrating immune cells is significantly increased, whereas treatment with the M-CSFR inhibitor GW2580 can inhibit monocyte migration and ameliorate atherosclerotic lesions [45].